Since the introduction of somatostatin receptor (sst) imaging using 123 I-Tyr 3 -octreotide [1] , peptide receptor imaging and radiotherapy (PRRT) has become an established modality in the management of neuroendocrine tumours (NET) [2] .
Based on the findings of a previous study [3] ) for Ga-HA-DOTATATE were >10.000 (sst1), 0.64±0.23 (sst2), >1,000 (sst3 and sst4) and 59.7±15.1 (sst5), and for Ga-DOTATATE were >10,000 (sst1), 0.67±0.25 (sst2), >1.000 (sst3), 822±327 (sst4) and >1,000 (sst5).
In a first PET study a 73-year-old patient suffering from a NET with unknown primary and liver metastases was investigated with 68 Ga-HA-DOTATATE and 68 Ga-DOTATATE. Both agents showed a possible small primary tumour in the midgut and five liver metastases that showed somewhat higher 68 Ga-HA-DOTATATE uptake (mean SUVmax 23.8 vs. 21.6). The visual detectability of three small liver metastases with low uptake was superior with 68 Ga-HA-DOTATATE.
In summary, 68 Ga-HA-DOTATATE provides high-quality images comparable to or better than those with 68 Ga-DOTATATE. Further clinical studies are needed to confirm these first results and explore the use of HA-DOTATATE agents for PRRT.
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